Project Grant K01HL174822
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $791,503 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2029. This research initiative investigates novel roles of the thrombin receptor Protease Activated Receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome (ARDS)....
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $814,387 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 1, 2025 through April 30, 2029, funds research investigating lung vascular Group 3 Innate Lymphoid Cell (ILC3) subpopulations and their roles in antibacterial immunity and vascular regeneration. The...
- The Broad Institute of MIT and Harvard received a $130,593 Project Grant awarded August 1, 2025, by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant funds a two-year research project (through July 31, 2027) investigating histone acetylation modulators' function in alveolar regeneration and disease pathogenesis. The research focuses on understanding how lysine acetyltransferase 8 (KAT8) and related epigenetic factors...
- This K08 career development award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $163,790 in obligated funding to support a five-year research training and mentorship program for Dr. Peter Moore at the University of Colorado-Denver. The award, effective August 1, 2025 through July 31, 2030, delivers integrated career development services designed to transform Dr. Moore into an independent physician-scientist....
- This $131,988 Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, supports research targeting determinants of SARS-CoV-2 host interaction in airways. Funded through the Cardiovascular Diseases Research program, the grant aims to identify master regulator proteins that mechanistically regulate SARS-CoV-2 interactions in the airways. Using organotypic airway epithelial culture and systems biology tools at Columbia University, the...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $811,370 Project Grant award effective September 1, 2025, through August 31, 2030, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The research investigates how YAP and TAZ, key regulatory proteins in the Hippo signaling pathway, control alveolar epithelial cell regeneration during lung repair and recovery. The project addresses critical...
- Federal Grant Award Summary Massachusetts General Hospital received a $761,615 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 21, 2025, with a completion date of June 30, 2030. The grant supports translational and clinical research investigating alveolar epithelial glycocalyx resilience in women experiencing Acute Respiratory Distress Syndrome (ARDS). The research addresses the mechanistic...
- Federal Project Grant Award Summary Tufts University School of Medicine received a $227,502 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of June 30, 2025, and completion date of January 31, 2028. This grant supports research to characterize lung resident B1 cells and their functional role in maintaining lung homeostasis during development. The research project will employ advanced...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $178,846 Project Grant to the University of California, San Diego, effective August 1, 2025, through July 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a prospective clinical research study investigating optimal ventilator management strategies for patients with Acute Respiratory Distress Syndrome (ARDS) on veno-venous extracorporeal membrane oxygenation...
- This $182,060 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports basic research investigating the role of the senescence marker protein p16INK4a in alveolar epithelial stem cell differentiation and lung injury repair. The grant, awarded to the Regents of the University of California, San Francisco on September 30, 2025, with completion targeted for November 29, 2026, funds research utilizing...
ENDOTHELIAL S1PR1 PROMOTES LUNG REPAIR IN POST-VIRAL ARDS - VIRAL RESPIRATORY INFECTIONS, SUCH AS INFLUENZA AND SARS-COV2, FREQUENTLY LEAD TO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS), A CONDITION WITH A MORTALITY UP TO 46%. ENDOTHELIAL INJURY, DYSFUNCTION AND THE RESULTANT VASCULAR HYPERPERMEABILITY CONTRIBUTE TO THE SEVERITY OF ARDS, PERSISTENCE OF LUNG INJURY, AND DYSREGULATED REPAIR WITH THE DEVELOPMENT OF FIBROSIS. WHILE SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1PR1) IS A KEY PROTECTIVE SIGNALING AXIS ON ENDOTHELIAL CELLS, THE ROLE OF S1PR1 SIGNALING IN THE RESOLUTION OF LUNG INJURY IN POST-VIRAL ARDS HAS NOT BEEN WELL EXPLORED. THE OBJECTIVE OF THIS APPLICATION IS TO DEFINE ENDOTHELIAL S1PR1-DEPENDANT PATHWAYS WHICH PROMOTE THE RE-ALVEOLARIZATION OF THE POST-VIRAL LUNG NEEDED TO PREVENT MORBID FIBROTIC OUTCOMES. WE HYPOTHESIZE THAT ENDOTHELIAL S1PR1 SIGNALING PROMOTES PRODUCTIVE LUNG REPAIR AFTER VIRAL INFECTION VIA BMP2 MEDIATED SUPPORT OF THE EPITHELIAL NICHE. THESE PRELIMINARY FINDINGS A NEW FACET TO THE PLEOTROPIC BENEFITS OF EC S1PR1 BEYOND ITS ESTABLISHED ROLE IN LIMITING VASCULAR HYPERPERMEABILITY AND HIGHLIGHT A NEED TO COMPREHENSIVELY VALIDATE THE THERAPEUTIC POTENTIAL OF AUGMENTING S1PR1 EXPRESSION TO LIMIT POST-VIRAL PULMONARY FIBROSIS. WE WILL TEST THIS HYPOTHESIS VIA TWO SPECIFIC AIMS: 1) DETERMINE THE MECHANISM OF ENDOTHELIAL S1PR1 MEDIATED EPITHELIAL REPAIR AFTER VIRAL-INDUCED ARDS, AND 2) DETERMINE HOW EC S1PR1 REGULATION CAN BE THERAPEUTICALLY AUGMENTED TO ATTENUATE POST-VIRAL FIBROSIS. THE PROPOSED RESEARCH WILL REVEAL NOVEL LINKS BETWEEN EC S1PR1 AND EPITHELIAL REGENERATION AND DIFFERENTIATION AFTER VIRAL INFECTION AND IDENTIFY REGULATORS OF ENDOTHELIAL FUNCTION WHICH CAN BE THERAPEUTICALLY TARGETED TO ATTENUATE POST- VIRAL FIBROSIS. DR. BRAZEE'S LONG-TERM GOAL IS TO BE AN INDEPENDENT BASIC AND TRANSLATIONAL INVESTIGATOR WITH A RESEARCH PROGRAM AIMED AT UNDERSTANDING THE CONTRIBUTIONS OF THE ENDOTHELIUM IN SUPPORTING PRODUCTIVE LUNG REPAIR PATHWAYS. THE PROPOSED K01 RESEARCH AIMS UTILIZE PRIOR TRAINING IN MOUSE MODELS OF INFLUENZA VIRUS INFECTION, FIBROTIC LUNG DISEASE, AND FUNDAMENTAL MOLECULAR BIOLOGY TECHNIQUES. IN ADDITION, THE PROJECT WILL NECESSITATE ADVANCED TRAINING IN VASCULAR AND EPITHELIAL BIOLOGY, G-PROTEIN COUPLED RECEPTOR (GPCR) SIGNALING, AND TRANSLATIONAL MODELING OF HUMAN DISEASE USING HUMAN DERIVED 3D ORGANOIDS AND PRECISION CUT LUNG SLICES. SUCCESSFUL COMPLETION OF THESE AIMS, TOGETHER WITH CONTINUED PROFESSIONAL DEVELOPMENT, WILL PROVIDE THE PROFICIENCIES NECESSARY TO ESTABLISH A PRODUCTIVE RESEARCH PROGRAM AND AN IMPACTFUL CAREER AS AN INDEPENDENT R01-FUNDED INVESTIGATOR.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 1/18/26 | ||
| Not listed | $0 | 6/16/25 | ||
| Not listed | $0 | 6/16/25 | ||
| Not listed | $161.2k | 7/24/24 | ||
| Not listed | $161.2k | 7/24/24 |